Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1981 Mar;43(3):367–377. doi: 10.1038/bjc.1981.57

In vivo combination of misonidazole and the chemotherapeutic agent CCNU.

D W Siemann
PMCID: PMC2010614  PMID: 7225287

Abstract

The response of intramuscularly growing KHT sarcomas to the chemotherapeutic agent (1-(2-cloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) alone or simultaneously with the chemical radio-sensitizer misonidazole (MISO) was assessed using either a tumour growth-delay assay or an in vivo-in vitro tumour-excision assay. Median tumour growth delay following the combination of 20 mg/kg CCNU and either 0.5 or 1.0 mg/g MISO was 19.5 and 21.5 days, compared to 10 days for this CCNU dose alone. A similar degree of enhanced tumour response by MISO (factor of approximately 2 in tumour growth delay) was seen in RIF-1 tumours treated with 20 mg/kg CCNU plus 1.0 mg/g MISO. Clonogenic cell-survival studies with KHT sarcomas demonstrated that MISO at doses of 0.25, 0.5 or 1.0 mg/g given simultaneously with a range of CCNU doses produced dose-modifying factors (DMFs) of 1.9, 2.1 and 2.4 respectively. Normal tissue toxicity assessed by an LD50/7 assay led to DMFs of 1.2 and 1.4 for CCNU doses combined with 0.5 and 1.0 mg/g MISO. Thus in this animal tumour model the combination of CCNU and MISO appears to lead to a potential gain by a factor of approximately 1.7.

Full text

PDF
367

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Begg A. C., Fu K. K., Kane L. J., Phillips T. L. Single-agent chemotherapy of a solid murine tumor assayed by growth delay and cell survival. Cancer Res. 1980 Jan;40(1):145–154. [PubMed] [Google Scholar]
  2. Blackett N. M., Courtenay V. D., Mayer S. M. Differential sensitivity of colony-forming cells of hemopoietic tissue, Lewis lung carcinoma, and B16 melanoma to three nitrosoureas. Cancer Chemother Rep. 1975 Sep-Oct;59(5):929–933. [PubMed] [Google Scholar]
  3. Bush R. S., Jenkin R. D., Allt W. E., Beale F. A., Bean H., Dembo A. J., Pringle J. F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl. 1978 Jun;3:302–306. [PMC free article] [PubMed] [Google Scholar]
  4. Clement J. J., Gorman M. S., Wodinsky I., Catane R., Johnson R. K. Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res. 1980 Nov;40(11):4165–4172. [PubMed] [Google Scholar]
  5. Conroy P. J., Sutherland R. M., Passalacqua W. Misonidazole cytotoxicity in vivo: a comparison of large single doses with smaller doses and extended contact of the drug with tumor cells. Radiat Res. 1980 Jul;83(1):169–189. [PubMed] [Google Scholar]
  6. Denekamp J., Hirst D. G., Stewart F. A., Terry N. H. Is tumour radiosensitization by misonidazole a general phenomenon? Br J Cancer. 1980 Jan;41(1):1–9. doi: 10.1038/bjc.1980.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dische S. Hyperbaric oxygen: the Medical Research Council trials and their clinical significance. Br J Radiol. 1978 Nov;51(611):888–894. doi: 10.1259/0007-1285-51-611-888. [DOI] [PubMed] [Google Scholar]
  8. Hill R. P., Bush R. S. The effect of misonidazole in combination with radiation dose fractionation. Br J Cancer Suppl. 1978 Jun;3:255–258. [PMC free article] [PubMed] [Google Scholar]
  9. Hill R. P., Stanley J. A. The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents. Cancer Res. 1975 May;35(5):1147–1153. [PubMed] [Google Scholar]
  10. Kallman R. F., Silini G., Van Putten L. M. Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J Natl Cancer Inst. 1967 Sep;39(3):539–549. [PubMed] [Google Scholar]
  11. Lelieveld P., Twentyman P. R., Kallman R. F., Brown J. M. The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors. VI. BCNU. Int J Radiat Oncol Biol Phys. 1979 Sep;5(9):1549–1552. doi: 10.1016/0360-3016(79)90769-7. [DOI] [PubMed] [Google Scholar]
  12. Rauth A. M., Chin J., Marchow L., Paciga J. Testing of hypoxic cell radiosensitizers in vivo. Br J Cancer Suppl. 1978 Jun;3:202–205. [PMC free article] [PubMed] [Google Scholar]
  13. Siemann D. W., Hill R. P., Bush R. S. The importance of the pre-irradiation breathing times of oxygen and carbogen (5% CO2: 95% O2) on the in vivo radiation response of a murine sarcoma. Int J Radiat Oncol Biol Phys. 1977 Sep-Oct;2(9-10):903–911. doi: 10.1016/0360-3016(77)90188-2. [DOI] [PubMed] [Google Scholar]
  14. Sridhar R., Koch C., Suterland R. Cytotoxicity of two nitroimidazole radiosensitizers in an in vitro tumor model. Int J Radiat Oncol Biol Phys. 1976 Nov-Dec;1(11-12):1149–1157. doi: 10.1016/0360-3016(76)90088-2. [DOI] [PubMed] [Google Scholar]
  15. Sutherland R. M., Eddy H. A., Bareham B., Reich K., Vanantwerp D. Resistance to adriamycin in multicellular spheroids. Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1225–1230. doi: 10.1016/0360-3016(79)90643-6. [DOI] [PubMed] [Google Scholar]
  16. Sutherland R. M. Selective chemotherapy of noncycling cells in an in vitro tumor model. Cancer Res. 1974 Dec;34(12):3501–3503. [PubMed] [Google Scholar]
  17. Tannock I. F. Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res. 1970 Oct;30(10):2470–2476. [PubMed] [Google Scholar]
  18. Twentyman P. R. An artefact in clonogenic assays of bleomycin cytotoxicity. Br J Cancer. 1977 Nov;36(5):642–644. doi: 10.1038/bjc.1977.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Twentyman P. R., Brown J. M., Gray J. W., Franko A. J., Scoles M. A., Kallman R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980 Mar;64(3):595–604. [PubMed] [Google Scholar]
  20. Wasserman T. H., Phillips T. L., Johnson R. J., Gomer C. J., Lawrence G. A., Sadee W., Marques R. A., Levin V. A., VanRaalte G. Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys. 1979 Jun;5(6):775–786. doi: 10.1016/0360-3016(79)90061-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES